clevercast
{"PLE04":{"id":"WdekGw","strictid":"PLE04","name":"PLE04","description":"","account_id":"2bK6rw","ts":0},"PLE05":{"id":"W9mpyj","strictid":"PLE05","name":"PLE05 Closing Ceremony + Concert","description":"","account_id":"2bK6rw","ts":1638855000},"SAT09":{"id":"VvyakX","strictid":"SAT09","name":"SAT09","description":"","account_id":"2bK6rw","ts":1638889200},"SPI07":{"id":"WwGDRw","strictid":"SPI07","name":"SPI07","description":"","account_id":"2bK6rw","ts":1638874920},"SCS14":{"id":"2avEmE","strictid":"SCS14","name":"SCS14","description":"","account_id":"2bK6rw","ts":1638874920},"SCS13":{"id":"A6nmKN","strictid":"SCS13","name":"SCS13","description":"","account_id":"2bK6rw","ts":1638874920},"KEY09":{"id":"Wlqkxg","strictid":"KEY09","name":"KEY09","description":"","account_id":"2bK6rw","ts":1638874920},"KEY06":{"id":"AGZbol","strictid":"KEY06","name":"KEY06","description":"","account_id":"2bK6rw","ts":1638873120},"KEY01":{"id":"AR1vr7","strictid":"KEY01","name":"KEY01","description":"","account_id":"2bK6rw","ts":1638871320},"PLE03":{"id":"VyOE09","strictid":"PLE03","name":"PLE03","description":"","account_id":"2bK6rw","ts":1638867600},"WEB05":{"id":"AKYxLw","strictid":"WEB05","name":"WEB05","description":"","account_id":"2bK6rw","ts":1638824520},"WEB04":{"id":"V316Xb","strictid":"WEB04","name":"WEB04","description":"","account_id":"2bK6rw","ts":1638817320},"KEY05":{"id":"WNKJlG","strictid":"KEY05","name":"KEY05","description":"","account_id":"2bK6rw","ts":1638811920},"SPI06":{"id":"VBXxdo","strictid":"SPI06","name":"SPI06","description":"","account_id":"2bK6rw","ts":0},"SCS12":{"id":"VYeD58","strictid":"SCS12","name":"SCS12","description":"","account_id":"2bK6rw","ts":1638810120},"SCS10":{"id":"VDrPkz","strictid":"SCS10","name":"SCS10","description":"","account_id":"2bK6rw","ts":1638810120},"KEY03":{"id":"W9mpEj","strictid":"KEY03","name":"KEY03","description":"","account_id":"2bK6rw","ts":1638810120},"SAT08":{"id":"VvyaNX","strictid":"SAT08","name":"SAT08","description":"","account_id":"2bK6rw","ts":0},"SAT07":{"id":"WwGD3w","strictid":"SAT07","name":"SAT07","description":"","account_id":"2bK6rw","ts":0},"SPI05":{"id":"VznBKn","strictid":"SPI05","name":"SPI05","description":"","account_id":"2bK6rw","ts":1638788520},"SCS11":{"id":"ApYQ5M","strictid":"SCS11","name":"SCS11","description":"","account_id":"2bK6rw","ts":1638788520},"SCS09":{"id":"2MnrZe","strictid":"SCS09","name":"SCS09","description":"","account_id":"2bK6rw","ts":1638788520},"SPI04":{"id":"Wlqkpg","strictid":"SPI04","name":"SPI04","description":"","account_id":"2bK6rw","ts":1638781320},"SCS08":{"id":"ALoQw5","strictid":"SCS08","name":"SCS08","description":"","account_id":"2bK6rw","ts":1638781320},"SCS07":{"id":"AGZbgl","strictid":"SCS07","name":"SCS07","description":"","account_id":"2bK6rw","ts":1638781320},"WEB03":{"id":"WokLe9","strictid":"WEB03","name":"WEB03","description":"","account_id":"2bK6rw","ts":1638738120},"SAT04":{"id":"Ak6yrj","strictid":"SAT04","name":"SAT04","description":"","account_id":"2bK6rw","ts":0},"SAT06":{"id":"WdekLm","strictid":"SAT06","name":"SAT06","description":"","account_id":"2bK6rw","ts":0},"KEY08":{"id":"WNKJwG","strictid":"KEY08","name":"KEY08","description":"","account_id":"2bK6rw","ts":1638716520},"KEY10":{"id":"2bzB4G","strictid":"KEY10","name":"KEY10","description":"","account_id":"2bK6rw","ts":0},"SCS04":{"id":"VPxn5l","strictid":"SCS04","name":"SCS04","description":"","account_id":"2bK6rw","ts":1638716520},"SCS03":{"id":"WdekLP","strictid":"SCS03","name":"SCS03","description":"","account_id":"2bK6rw","ts":1638716520},"SPI02":{"id":"21a6D6","strictid":"SPI02","name":"SPI02","description":"Societal impact of influenza and COVID-19","account_id":"2bK6rw","ts":1638702120},"KEY02":{"id":"VznBQJ","strictid":"KEY02","name":"KEY02","description":"","account_id":"2bK6rw","ts":1638702000},"SCS06":{"id":"ApYQJq","strictid":"SCS06","name":"SCS06","description":"Innate and adaptive immunity towards influenza, RSV disease and COVID-19","account_id":"2bK6rw","ts":1638702120},"SPI01":{"id":"AZzDlk","strictid":"SPI01","name":"SPI01","description":"Why influenza is a priority for policy makers","account_id":"2bK6rw","ts":1638694920},"SCS02":{"id":"Wj0kJZ","strictid":"SCS02","name":"SCS02","description":"Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology","account_id":"2bK6rw","ts":1638694920},"SCS01":{"id":"24amLe","strictid":"SCS01","name":"SCS01","description":"Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection","account_id":"2bK6rw","ts":1638694920},"WEB02":{"id":"Ak6yJr","strictid":"WEB02","name":"WEB02","description":"Childhood Influenza vaccination and treatment in a COVID-19 era","account_id":"2bK6rw","ts":1638651720},"OPN01":{"id":"WqYk9o","strictid":"OPN01","name":"OPN01","description":"Opening Ceremony\n","account_id":"2bK6rw","ts":1638637200},"KEY04":{"id":"27y68N","strictid":"KEY04","name":"KEY04","description":"COVID coagulopathy in comparison to influenza and pneumococci sepsis","account_id":"2bK6rw","ts":1638694920},"PER01":{"id":"2bzBJX","strictid":"PER01","name":"Permanent Livestream","description":"","account_id":"2bK6rw","ts":0},"SAT03":{"id":"VBXxaB","strictid":"SAT03","name":"SAT03","description":"","account_id":"2bK6rw","ts":1638630000},"SAT02":{"id":"VYeDlQ","strictid":"SAT02","name":"SAT02","description":"INFLUENZA AND COVID-19 Burden of Disease and Prospects for Vaccination","account_id":"2bK6rw","ts":1638622800},"SAT01":{"id":"VBXxPX","strictid":"SAT01","name":"SAT01 ","description":"Post-COVID lockdown era: what are we facing?","account_id":"2bK6rw","ts":1638615600},"WEB01":{"id":"VYeD8w","strictid":"WEB01","name":"WEB01","description":"Vaccination in a COVID-19 era","account_id":"2bK6rw","ts":1638644520},"SAT05":{"id":"ApYQNa","strictid":"SAT05","name":"SAT05","description":"Will be streamed by Roche, not from studio Antwerp, BE","account_id":"2bK6rw","ts":1638709200}}
clevercast items
{"LAN01":{"id":"WEBElL","strictid":"LAN01","name":"Lange testtrailer","description":"","account_id":"2bK6rw","chapters":[]},"TES01":{"id":"W9Jpob","strictid":"TES01","name":"Testtrailer","description":"Test trailer for scheduling Pseudo Live Events","account_id":"2bK6rw","chapters":[]}}
Sun 5 Dec
Sunday
5
December

Sunday 5 December, 10:00 - 11:45 CET

Why influenza is a priority for policy makersSPI01

Time:

Sunday 5 December, 10:00 - 11:45 CET

Track:

Science Policy Interface


Chair:
Roman Prymula, Charles University Prague

Programme:
  1. Keynote opening: The future European Union for Health to fight influenza

    Dolors Montserrat, European Parliament, Spain
  2. Effectiveness of adjuvanted trivalent vaccine (aTIV) for influenza over 18 epidemic seasons

    Francesco Lapi, Health Search, Italian College of General Practitioners and Primary Care, Italy
  3. Public health benefits of switching into a recombinant quadrivalent vaccine in the Spanish Murcia and Valencia regions the recommended adult population (18+) for influenza seasonal vaccination.

    Georgina Drago Manchón, Sanofi Pasteur, Barcelona, Spain
  4. Open Science Practices Are Favored by Most Surveyed Influenza Researchers Despite A Lack of Perceived Peer Support

    Kelly Sutherland, The Center for Open Science, United States of America

Sunday 5 December, 12:00 - 13:45 CET

Societal impact of influenza and COVID-19SPI02

Time:

Sunday 5 December, 12:00 - 13:45 CET

Track:

Science Policy Interface


Chair:
Terho Heikkinen, University of Turku

Programme:
  1. The importance of vaccinating children against influenza

    Terho Heikkinen, University of Turku, Finland
  2. The Economic Burden of Influenza Among Adults Aged 18-64: A Systematic Literature Review

    Caroline de Courville, Sanofi Pasteur, France
  3. Evaluation of Psychometric Properties of a Patient-Reported Outcome Measure for the Assessment of COVID-19 Signs and Symptoms: A Cross-Sectional Observational Study

    Eric K. H. Chan, Janssen Global Services LLC, Raritan, NJ, United States of America
  4. Qualitative Interviews from a Cross-Sectional Study to Support the Content Validity of a Patient-Reported Outcome Measure of COVID-19 Signs and Symptoms in Adults

    Carla DeMuro Romano, RTI Health Solutions, Research Triangle Park, NC, United States of America
Mon 6 Dec
Monday
6
December

Monday 6 December, 10:00 - 11:45 CET

Benefits of vaccinating healthcare workers and other risk groupsSPI04

Time:

Monday 6 December, 10:00 - 11:45 CET

Track:

Science Policy Interface


Chair:
Antonia Ho, University of Glasgow

Programme:
  1. Introductory lecture on Benefits of vaccinating healthcare workers and other risk groups

    Antonia Ho, University of Glasgow, United Kingdom
  2. Influenza vaccination coverage rates during the COVID-19 pandemic: data from seven countries in the Northern Hemisphere

    Marco Del Riccio, Netherlands Institute for Health Services Research, Italy; Postgraduate Medical School in Public Health, University of Florence, Italy
  3. Attitude and beliefs about the seasonal influenza vaccination among Health Care Workers during Covid19 Pandemic- Kashmir, India

    Hyder Manzoor, Sheri kashmir institute of medical sciences, India
  4. Cost-Effectiveness of High-Dose Quadrivalent Influenza Vaccine (HD-QIV) Versus Adjuvanted Quadrivalent Influenza Vaccine (aQIV) in the Italian elderly population

    Filippo Rumi, Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma, Italy.

Monday 6 December, 12:00 - 13:45 CET

Risk assessment and risk communication in acute respiratory virus infectionsSPI05

Time:

Monday 6 December, 12:00 - 13:45 CET

Track:

Science Policy Interface


Chair:
Barbara Rath, Vienna Vaccine Safety Initiative

Programme:
  1. Understanding the variability of risk preferences for influenza vaccination among older adults (50+) during Covid19 times: a 8-country survey

    Frederic Bouder, University of Stavanger, Norway
  2. Covid-19 response in Ireland: Vaccine risk communication

    Donal O'Connor, Health Products Regulatory Authority, Ireland
  3. ImmuHubs: Improving access to vaccination in disadvantaged and difficult to reach populations

    Barbara Rath, Vienna Vaccine Safety Initiative, Germany
  4. Developing vaccine demand interventions using behavioural science and digital and social marketing practices

    Angus Thomson, UNICEF, France

Monday 6 December, 18:00 - 19:45 CET

Global health perspectives on acute respiratory virus disease and how to ensure equitable accessSPI06

Live
Time:

Monday 6 December, 18:00 - 19:45 CET

Track:

Science Policy Interface


Chair:
Ann Moen, Centers for Disease Control

Opening keynote lecture by Prof. Dr. Kwabena Frimpong-Boateng, Ghana’s Presidential Committee on Vaccine Development and Production Faculty lectures:

  • APACI: Marie-Louise McLaws
  • IFPMA: Beverley Taylor
  • African Union Commission on COVID-19: Lwazi Manzi 
  • The Rockefeller Foundation: Bruce Gellin
  • GAVI: Marta Tufet

Panel discussion Faculty lectures

  • Ready2Respond: Marie Mazur
  • PIVI: Joe Bresee
  • MOH-CDC Albania: Silvia Brino
  • MOH Armenia: Gayane Sahakyan

Panel discussion

Closing remarks

Tue 7 Dec
Tuesday
7
December

Tuesday 7 December, 12:00 - 13:45 CET

Pandemic Preparedness Planning in PeacetimeSPI07

Live
Time:

Tuesday 7 December, 12:00 - 13:45 CET

Track:

Science Policy Interface


Chair:
Ab Osterhaus, TiHo, Hannover

Introductory talk: Advancing Pandemic and Seasonal Influenza Preparedness and Response

Dr. Victor Dzau, President of the Institute of Medicine, United States of America

Non-medical interventions: recommendations and lessons learned from COVID-19 for influenza

Prof. Patricia Garcia, School of Public Health, Cayetona Heredia University, Chile

Panel discussion

  FILTER